Merck’s Keytruda Dominance Isn’t at Risk From New Cancer Rivals

(Bloomberg) -- Merck & Co.’s top-selling cancer drug Keytruda is still the talk of Wall Street despite positive results from Roche Holding Ag’s Tecentriq and Bristol-Myers Squibb Co.’s combination ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.